IL18RAP

Across TCGA pan-cancer cohorts, IL18RAP Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated IL18RAP data layer compared with 27 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in thyroid carcinoma (THCA), where higher IL18RAP Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated IL18RAP expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

THCA, LUSC, and UCEC are the cancer types where IL18RAP Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
THCA	OS	Median	All	0.255	0.954	<.001	20	view →
LUSC	OS	Median	II,III,IV	0.180	0.616	.008	19	view →
UCEC	DFS	Median	All	0.959	0.624	.019	8	view →
LGG	OS	Median	All	0.208	0.889	<.001	6	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

IL18RAP–THCA (OS)

Open the THCA breakdown →